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SUMMARY 
The last few years have seen the development of a branch of somatic gene therapy which aims at strengthening the 
immune surveillance of the body, leading to eradication of disseminated cancer tumor cells and occult micrometastases 
after surgical removal of the primary tumor. Such a tumor vaccination protocol calls for cultivation of the primary 
tumor tissue and the insertion of one of three types of genes into the isolated cultured tumor cells followed by irradiation 
of the transfected or transduced cells to render them incapable of further proliferation. The cells so treated constitute 
the ‘tumor vaccine’. A review of the literature suggests that for mouse models, in the initial period after inoculation, 
rejection of the tumor cells is usually effected by non-T-cell immunity, whereas the long-term systemic immune response 
is based on cytotoxic T-cells. High expression of the gene inserted into the tumor cells may be critical for the success 
of the vaccination procedure. Examples are given which indicate that transferrinfection, a procedure to introduce genes 
by adenovirus-augmented receptor-mediated endocytosis, meets some important prerequisites for successful application 
of this type of gene therapy. 
INTRODUCTION 
The major obstacle to immunotherapy of cancer is the 
poor immunogenicity of tumors, especially in man. This 
is somewhat surprising since the large number of genetic 
alterations found in advanced cancers should give rise to 
peptide neo-epitopes capable of being recognized in the 
context of MHC-I molecules by cytotoxic lymphocytes 
(Lurquin, 1989). Indeed, tumor-associated (Groen, 1987) 
and tumor-specific antigens (Van der Bruggen and Van 
den Eynde, 1992) which should be targets for immunolog- 
ical attack have recently been identified. It is therefore 
possible that the immune system fails to eliminate tumors 
not because neoantigens are absent, but rather because 
the response to these neoantigens is inadequate (Fearon 
et al., 1990). 
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(a) Introduction of certain genes elicits a systemic 
immune response against tumor ceils 
In recent years it has been discovered that transfection 
of certain genes into tumor cells can render them more 
immunogenic and, therefore, less tumorigenic. These 
genes fall into three categories. 
( 1 ) Genes expressing proteins which are,foreign to the 
rrpertoire c$ tutnur cells 
Such xenogenizatjon of tumor cells can be brought 
about, for example, by expressing syngeneic MHC-I anti- 
gens in MHC-I deficient tumor cells, expressing allo- 
geneic MHC-I or MHC-II antigens or expressing viral 
proteins such as hemagglutinin (for references see 
Table I). Xenogenization can also be brought about by 
mutagenesis of tumor cells (Van Pel and Boon, 1982) to 
yield Turn- cell clones which elicited a rejection response 
in syngeneic mice (reviewed in Van der Bruggen and Van 
den Eynde, 1992). 
The goal of this operation is to activate the immune 
system so that it recognizes the tumor cells as foreign 
and rejects them. The insertion of cytokine-encoding 
genes such as itlterlcukin. colony stit~uI~~ting factor and 
interferoll-eI~coding genes, into tumor cells nearly uni- 
formly reduces the tumorigenicity of injected tumor cells 
with the known exceptions o far of IL-6 which actually 
leads to an accelerated growth of injected cells, and of 
TNF-cx or IFN-y, where only partial reduction of tumori- 
genicity is obtained (see Table II). In most instances, 
where tested. a systemic protection against the parental 
tumor has been observed. However, no such systemic 
protection was detected after IL-4 (exception see 
Columbek et al., 1991), G-CSF or TNF-x transfection 
of tumor cells (see Table II ). 
( 3 f Genes rncoding ricirssary proteins 
The properties of xenogenized tumor cells have been 
explained by the concept of associative recognition (Lake 
and Mitchison, 1976; 1977; Kenne and Foreman, 1982) 
which proposes that minor cell surface antigenic differ- 
ences (as in the case of cancer cells) are insu~cient for 
the induction of an immune response, The addition of 
more powerful antigens to the cell surface not only pro- 
vides for a response to the added antigens but also 
induces immunorecognition of the original tumor-associ- 
ated cell-surface antigens (Fearon et al., 1988) and sys- 
temic protection against the tumor cell (see Table I). 
The aim of this operation is to impart features of anti- 
gen presenting cells to the tumor cells. The CD28 antigen 
on CD4+ and CD8’ T-cells is the primary receptor for 
the activating antigen B7. CD28 binds to B7 in the ab- 
sence of other accessory molecules. Interaction between 
these two antigens is co-stimulatory for T-cell activation 
(Linsley et al., 1991). The two-signal model (Janeway, 
1989; Nossal, 1989: Schwartz, 1989) postulates that for 
optimal activation lymphocytes require both an antigen- 
specific signal delivered through the T-cell receptor and 
a second signal, a non-specific o-stimulatory signal such 
as B7. 
The precursor of these xenogenization experiments uti- 
lizing gene transfer is the systemic protection elicited 
against tumor cells by infecting them with virus express- 
ing new antigens on tumor cells or yielding viral oncoly- 
sates (Lindenmann and Klein, 1967; Wallack et al., 1977; 
Ito et al., 1990; Lehner et al., 1990; Liebrich et al., 1991). 
This model suggests that immunogenic tumors which 
do not express I37 can escape destruction by the immune 
response because tLirnor-targeted T-cells receive inade- 
quate co-stimulation. This leads to the proposition that 
transfer of a gene encoding the co-stimulatory ligand B7 
into melanoma cells, when introduced into a syngeneic 
mouse, would induce rejection of these cells in vivo. 
Recently two groups (Chen et al., 1992; Townsend and 
TABLE I 
Genes used to xenogenize tumor cells 
Tumor model Xenogizing gene Tumorigenicity Systemic protection Reference 
Lewis lung carcinoma 
Colon adenocarcinoma CT26 
Fats 3 
Lung carcinoma 
3LL-Dl22 
Sal sarcoma 
Lung carcinoma 
3LL-Dl22 
allogeneic H-2Ld 
MHC-I 
hemagglutinin 
l3ein~~~littinil3 
svngeneic H-2Kb 
iM &-I 
Ak, and .qj 
MHC-II 
c-for 
yes 
yt% 
yes 
yes 
yes 
n.d. 
1taya et al. (1987) 
P%arnn et al. I 1988) 
Fcaron et ai. I 19881 
Plaksin et at. t 198X) 
Nostrand-Rosenberg et al. t 1990) 
Kushtai et al. ( 1990) 
ah. =absent: n.d. = not done. 
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TABLE II 
‘Tumor vaccines’ produced by the transfer of cytokines into tumor cells 
Ctk” Tumor model Mode of Transf. Cytokine production Tumorigenicityb Systemic Reference 
generation cells protection” 
- 
IL-2 Colorectal carcinoma 
CAT26 
Melanoma B16 
Sarcoma CBA-SP, 
Dunning prostate 
carcinoma 
Fibrosarcoma CMS-5 
Ca+PO, Q 300 u/10’ cells/24 h 
clones 
ab. yes 
yes 
yes 
yes 
yes 
n.d. 
Fearon et al. 
(1990) 
Rat sarcoma HSNLV 
Mastocytoma P815 
Mastocytoma P815 
Rat medullary thyroid 
carcinoma 
Lewis lung carcinoma LLC 
Lewis lung carcinoma 3LL- 
D122 
Melanoma M3 
IL-4 Plasmacytoma 5558 
Mammary adenocarcinoma 
K485 
Renal carcinoma RENCA 
Lewis lung carcinoma LLC 
IL-6 Plasmacytoma 5558 
IL-7 
G- 
CSF 
M- 
CSF 
GM- 
CSF 
IFN-y 
Ependymoblastoma 203 
glioma 
Plasmacytoma J558L 
Mammary adenocarcinoma 
TS/A 
Colon adenocarcinoma 
C26 
Plasmacytoma J558L 
Melanoma B16 
Neuroblastoma Cl300 
Fibrosarcoma CMS-5 
Squamous cell carcinoma 
Pam-T 
Adenocarcinoma SP1 
CT26 
TNF-y Plasmacytoma 5558 
Sarcoma MCA-205/WP-4 
JJ3 DukxB-11 
transduction 
transduction 
Ca*PO, 
Ca. PO, 
Ca*PO, 
lipofection 
transduction 
receptor-mediated 
gene transfer 
electroporation 
Ca*PO, 
Ca*PO, 
lipofection 
electroporation 
electroporation 
electroporation 
transduction 
electroporation 
transduction 
transduction 
transduction 
transduction 
cell 
line 
cell 
line 
cell 
line 
cell 
line 
pooled 
clones 
cell 
line 
cell 
line 
pooled 
cells 
cell 
line 
cell 
cell 
line 
cell 
line 
cell 
line 
cell 
line 
cell 
line 
cell 
line 
cell 
line 
< 30 u/ml 
<2500 u/lo6 cells/24 h 
4 3000 u/lo6 cells/24 h 
<3500 u/lo6 cells/24 h 
50 u/lo6 cells/24 h 
,< 100 u/lo6 cells/24 h 
< 7 u/ml 
< lo5 u/10’ cells/24 h 
< 29 000 u/lo6 cells/24 h 
< 2800 u/lo6 cells/24 h 
- 15 000 u/lo6 cells/24 h 
35 ng/ml 
500 u/ml 
& 250 u/ml 
4-65 u/ml 
50 u/ml 
<450 pg/ml 
< 100 u/ml 
pooled 1500 ng/106 cells/24 h 
cells 
cell 
line 
cell 
line 
cell 
line 
< 50 u/ml 
<25 u/ml 
< 200 u/ml 
Ca.PO,/lipofection pooled 256 u/ml 
clones 
cell ~64 u/ml 
line 
transduction 
transduction 
cell 
line 
cell 
line 
< 40 pg/ml 
420 pg/106 cells/24 h 
polybrene pooled - 
clones 
ab. 
ab. 
ab. 
ab. 
ab. 
ab. 
ab. 
ab. 
ab. 
ab. 
ab. 
ab. 
act. 
ab. 
ab. 
ab. 
ab. 
part. 
ab. 
ab. 
ab. 
part. 
ab. 
part. 
part. 
part. 
ab. 
yes 
n.d. 
nd. 
(yes) 
yes 
yes 
no 
no 
(yes) 
no 
nd. 
yes 
n.d. 
n.d. 
(no) 
nd. 
yes 
yes 
yes 
n.d. 
(no) 
nd. 
n.d. 
no 
nd. 
Gansbacher 
et al. ( 1990a,b) 
Russell et al. 
(1991) 
Ley et al. (1991) 
Roth et al. 
(1992) 
Ohe et al. (1993) 
Porgador et al. 
(1993) 
this paper 
Tepper et al. 
(1989) 
Tepper et al. 
(1992) 
Golumbek et al. 
(1991) 
Ohe et al. (1993) 
Blankenstein 
et al. (1991) 
Akoi et al. 
(1992) 
Hock et al. 
(1991) 
Colombo et al. 
(1991) 
Dorsch et al. 
(1993) 
Dranoff et al. 
(1993) 
Watanabe et al. 
(1989) 
Gansbacher 
et al. (1990a,b) 
Maraguchi et al. 
(1991) 
Esumi et al. 
(1991) 
Blankenstein 
et al. (1991) 
Asher et al. 
(1991) 
Rollins and 
Sunday (1991) 
“Ctk =cytokine. 
bab. = absent or strongly reduced, depending on the level of cytokine production; part. = partial tumorigenicity; act. = accelerated. 
‘nd. = not done. 
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Allison, 1993) showed that this concept is indeed valid 
for melanoma cells. Rejection of B7-transfected tumor 
cells was primarily mediated by CD8’ T-cells and anti- 
CD4 antibodies ablating CD4 cells had no effect. 
Moreover, a systemic protection against the parental B7 
tumor cells was obtained (Chen et al., 1992; Townsend 
and Allison, 1993). These results open the door for experi- 
mentation with other accessory, co-stimulatory molecules 
which impart certain features of antigen presenting cells 
to tumor cells. The introduction of syngeneic MHC-II 
antigen (Table I) may also change the properties of tumor 
cells so that they present tumor antigens in the MHC-II 
context which can be recognized by T-helper cells, result- 
ing in an immunological cascade and eventual eradica- 
tion of the tumor cell. 
(b) In some instances initial rejection of the tumor cells is 
based on non-T-cells 
Interestingly, tumorigenicity of tumor cells during the 
‘vaccination’ step (initial injection) is also strongly dimin- 
ished for IL-4 and G-CSF-secreting tumor cells when 
tested in nude mice which are deficient for T-cells 
(Colombo et al., 1991; Golumbek et al., 1991). This sug- 
gests that the initial rejection of tumor cells is supported 
by a non-T-cell response. By contrast, no reduction of 
tumorigenicity is seen in nude mice in the case of IL-7 
and IFN-y-secreting tumor cells (see Table III). This is 
an indication that IL-7 and IFN-y induce a T-cell medi- 
ated immune response in immune competent mice. 
Results obtained for IL-2 varied according to the 
TABLE III 
Tumorigenicity of tumor cells transfected or transduced with cytokines 
Tumorigenicity 
in nude mice 
Cytokinc Reference 
I L-2 abolished cited in Buhenik et al. ( 1990) 
abolished Hock ct al. ( 1993) 
abolished” Porgador et al. ( 1993) 
no rcductionb Russell et al. ( 1991 ) 
I L-4 
IL-7 
G-CSF 
IFN-y 
abohshed 
no reduction 
abolished 
no reduction 
abolished 
Tepper et al. ( 1989) 
Golumbek et al. ( 1991 I 
Hock et al. (1991; 1993) 
Colombo et al. (1991) 
Watanabe et al. (19X9) 
Esumi et al. (1991) 
Hock et al. (1993) 
TNF-n weakened 
abolished 
Blankenstein et al. ( 1991 ) 
Hock et al. I 1993) 
“In high IL-2 producers 
bin low IL-2 producers. 
tumor model chosen, the number of cells itijcctcd and 
levels of cytokinc secretion. Thus a whole spectrum o1 
results has been reported, from no reduction of tumorige- 
nicity in nude mice (Ohe et al.. 1993) to partial and full 
rejection of IL-2-producing tumor cells, depending on the 
level of IL-2 secretion (Russell et al., 1991: Porgador et ~11.. 
1993). These findings have been interpreted as meaning 
that for low secretors, reduction in tumor growth in 
immune competent mice is mostly due to T-ceil activity, 
whereas for high IL-2 secretors a non-T-cell dependent 
mechanism is at work (Porgador et al., 1993). This is in 
accordance with the finding that T-cells arc stimulated 
via high-affinity heterodimeric IL-2 receptors which are 
expressed following antigen activation. NK cells. LAK 
precursors and macrophages are stimulated initially via 
constitutively expressed intermediate-affinity IL-2 recep- 
tors and thus require a higher concentration of IL-2 
(Porgador et al.. 1993, and references therein). 
The results tabulated in Table III can be correlated 
with histological investigations of the injection sites in 
immunocompetent mice. The initial injection sites after 
inoculation of, IL-4-producing RENCA cells are in- 
filtrated by activated macrophages and granulocytes 
(Golumbek et al., 1991). Similarly IL-4-producing plas- 
macytoma cells evoke infiltrated eosinophiles and macro- 
phages (Tepper, 1992). G-CSF-producing tumor cells 
show infiltration of neutrophilic granulocytcs. Thus, in 
the case of IL-4 and G-CSF the presence of non-T-cells 
at the injection sites correlates with the rejection of the 
tumor cells in the nude mouse test system. Moreover. 
NK cells are not likely to be involved. since NK-depicted 
mice are nevertheless protected from tumor development 
(Columbo et al., 1991). In the same vein, IFN--f- 
producing tumor cells show infiltration of Thy I ’ small 
lymphocytes (Watanabe et al.. 1989) whereas 
IL-7-producing, and in some cases IL-2-producing, cells 
(Pardoll, 1992) are marked by infiltration of T-cells as 
well as macrophages (Hock et al.. 1991 ). This again corrc- 
lates with the data in Table III where the nude mouse 
system fails to reject IFN-;I- and IL-7-producing tumor 
cells. As already mentioned the behavior of IL-2 pro- 
ducers is not uniform. In some systems the inocula arc 
infiltrated by T-cells (Pardoll, 1992) while in others the 
presence of macrophages and mast cells has been noted 
(Fearon et al., 1990). 
A recent study is particulary informative (Hock et al., 
1993) because the behavior of a single tumor cell line 
(5558) secreting a series of difierent cytokines has been 
investigated. At early times after injection of the inocula. 
IL-2-, IL-4-, TNF-lx- and IFN-n/-producing 5558 cells 
showed suppressed tumorigenicity in the immunodefi- 
cient nude, SCID, beige and NIHIII mice, but tumors 
eventually arose with a delay of 3 weeks in comparison 
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with mice injected with the parental cell line. 
IL-7-producing tumor cells were not rejected. This is con- 
firmatory evidence that most cytokines can elicit a T-cell- 
independent mechanism capable of suppressing tumor 
growth in a first, early phase after injection. The late 
outgrowth of tumors noted above was shown to be corre- 
lated with a partial or complete loss of cytokine pro- 
duction in cytokine-producing cells presumably through 
a selection process for a non-cytokine-producing popula- 
tion of cells. 
A correlation of the behavior of the tumors with the 
immunohistology of the injection site after 3-13 days in 
immunocompetent mice has been made (Hock et al., 
1993): IL-2-, IL-7- and TNF-a-producing inocula were 
already infiltrated by T-cells at early time points. T-cells 
were also observed in IL-4-producing tumors but not 
until 1 week after injection. In the case of IL-2 producers, 
CD8+ but not CD4+ infiltrates could be found. IL-7- 
and IFN-y-secreting tumors were densely infiltrated with 
both CD4+ and CD8+ cells. However, the predominant 
cell type found in the infiltrates of all cytokine producers 
excepting IL-7 producers were macrophages, which pre- 
sumably accounts for the rejection of these tumors in the 
nude mouse at early times. 
(c) Systemic long-term tumor rejection is based on CTLs 
Mice which have been immunized with transfected 
tumor cells producing a variety of cytokines such as IL-2, 
IL-4, GM-CSF, or IFN-)I, develop a systemic immune 
response which protects the animals from tumor growth 
after challenge with non-transfected tumor cells at a site 
distant from the primary immunization site (see also 
Table II). This protective activity is maintained for a pro- 
longed period of time. For instance, Gansbacher et al. 
(1990a,b) observed complete protection in a CMS-5 
fibrosarcoma model, even when the challenge was per- 
formed 6 weeks after the immunization with IFN-y- 
secreting tumor cells. Ley et al. (1991) demonstrated 
partial prevention of tumor growth when the challenge 
was made 90 days after immunization with 
IL-2-producing mastocytoma cells. Fearon et al. (1990), 
however, found a less persistent protection in a colon 
carcinoma model where the immune response induced by 
IL-2-transfected CT26 cells lost 50% of its efficacy within 
4 weeks. 
There are several ines of evidence that this prolonged 
systemic immune response is mediated by CTLs. Many 
groups (e.g., Fearon et al., 1990; Gansbacher et al., 
1990a,b; Golumbek et al., 1991; Ley et al., 1991; Dranoff 
et al., 1993) have demonstrated an increase of CTL activ- 
ity upon immunization with cytokine expressing tumor 
cells. The actual contribution of CTLs to tumor rejection 
has been confirmed in that depletion of CD8+ cells in 
immunized mice abolishes the ability to suppress tumor 
growth. In the case of GM-CSF-producing B16 mela- 
noma cells, CD4+ T-cells are required in addition to 
CD8+ cells for systemic protection (Dranoff et al., 1993). 
The observation that the systemic immune response is 
specific to the tumor used for immunization, and that the 
growth of non-cross-reactive syngeneic tumors is not 
affected, underlines the role of CTLs for the generation 
of a tumor-specific, MHC-I-restricted, systemic immune 
response against the parental tumor in these models 
(Fearon et al., 1990; Gansbacher et al., 1990a,b). 
(d) Transferrinfection of tumor cells meets several 
requirements for efficient vaccine production 
The proposed immunization procedure in man calls 
for the following steps: (i) Operative removal of the pri- 
mary tumor tissue; (ii) culture of the tumor cells in vitro; 
(iii) transfection or transduction of tumor cells with the 
chosen gene or combination of genes; (iv) irradiation of 
the tumor cells to prevent their proliferation; (v) subcuta- 
neous or intradermal injection of the treated tumor cells 
into the patient. 
Since the tumor tissue may be heterogeneous due to 
tumor progression it may be desirable not to select for 
transfected or transduced cell clones, as has been done 
in most experiments reported up to now (see Table II). 
This procedure, besides being time consuming and delay- 
ing unnecessarily the application of the ‘tumor vaccine’, 
may inadvertently lead to selection of an unrepresentative 
cell clone. Furthermore, extensive culturing and expan- 
sion of cells may lead to a loss of the tumor antigen. A 
procedure by which the bulk of the tumor cells can be 
transfected soon after removal and culture would seem 
desirable. 
We believe that our recently developed transferrinfec- 
tion procedure (Cotten et al., 1992; Curie1 et al., 1992; 
Wagner et al., 1992; Zatloukal, 1992) has many advan- 
tages over retroviral transduction or DNA transfection 
followed by clonal expansion of the genetically modified 
cells (see Table II). 
Transferrinfection is a new transfection protocol in 
which the plasmid DNA to be transported into the tumor 
cell is reacted with transferrin-polylysine to form highly 
condensed round particles with a diameter of approx. 
100 nm, referred to as ‘donuts’ (Zatloukal et al., 1992). 
These ‘donuts’ are linked to Ad5d1312 or AdSd11014, 
which, owing to its endosomolytic property, greatly en- 
hances the receptor-mediated transfer of genes into cells 
and ultimately into the cell nucleus (Cotten et al., 1992; 
Curie1 et al., 1992; Wagner et al., 1992; Zatloukal et al., 
1992). We show below that transferrinfection of tumor 
cells with IL-2-producing plasmids leads to secretion of 
cytokines at high levels (cf. Table II), eradicates tumori- 
TABLL IV 
Loss of tumorigenicity of transfccted M3 melanoma cells with DBA:2 
mice 
_ 
Gene transfer 
No gene 
transfer 
IL-2 
I FN-*{ 
Appearance of tumors 
[weeks (w) after tumor ceil irnpl~lntation~~ 
O/6 6:6 6% 66 h;6 h/6 6;6 
06 0% O/6 O/h Oi’6 O/6 ($6 
O/6 O/6 I:6 1% I/h l/h I:6 
“To generate the transfer complexes. 2 x 10” biotinylated Ad5d1312 in 
100 ml HBS (20 mM Hepesjl50 mM NaCl) was mixed with streptavidi- 
nylated poiylysine (0.5 ug) in 100 ml HBS and incubated for 30 min at 
room temperature. Thereafter, 6 ug of plasmid DNA (IL-2 or IFN-y) 
in 150 ml HBS were added, mixed thoroughly and incubated for 30 
min. Finally, polylysine-modified human transferrin (7.5 ug) in 150 ~1 
HBS were added, mixed thoroughly and incubated for a further 30 min. 
For transf~ction the complexes were applied to M3 cells (3 x 10’) in a 
total volume of 2 ml culture medium. After 4 h of incubation at 37 C 
the complex-containing medium was removed and fresh medium con- 
taining serum was added. The cells were then trypsinized and washed 
twice in Ham’s F10 culture medium without serum. IO5 M3 cells not 
tram&ted or transfected with IL-2 or tFN-*/ plasmids were applied 
subcutaneousiy into the backs of each of six anesthcsized DBAQ mice. 
Tumors were scored at weekly intervals. 
genicity and yields systemic protection against a chal- 
lenge with live tumor cells. 
(e) Loss of tumorigenicity in transferrinfected murine 
melanoma M3 cells 
The murine melanoma cell line Cloudman S91 (clone 
M3) was obtained from ATCC (No. CCL53.1). M3 cells 
which were established from a spontaneously developed 
melanoma in DBA/Z mice (Cloudman, 1941)“” express 
low levels of MHCI antigens (unpublished observation) 
and are only moderately immunogenic. The cells were 
cultured in 0.1% gelatin-coated &cm plastic dishes or 
T25 culture flasks in Ham’s FlO medium containing 
12.5% horse serum/2.5% fetal calf serum/2 mM gluta- 
mine and antibiotics. In order to demonstrate loss of 
tumorigenicity of the M3 cells upon transfection with 
IL-2 or IFN-21 genes driven by CMV promoter cells were 
applied subcutaneously into the backs of six anesthesized 
DBA/2 mice. IL-2 production prior to injection but after 
irradiation was at 2400 units/lo6 cells per 24 h and IFN-1, 
production was 865 ng/lO’ cells per 24 h. Tumors were 
scored at weekly intervals. 
As can be seen in Table IV the control mice all devel- 
oped tumors within 2 weeks after inoculation. All mice 
challenged with IL-2-producing M3 cells remained free 
**Note that the information given by .4TCC on CCL 53.1 Clone M3 
(Cloudman S 91 melanoma) is erroneous with respect to the synge- 
neic host. 
of tumors. while in the case of IFN-;t 5.6 relnaiil~d tumor- 
free. The results obtained show that the highly tumori- 
genie M3 cells losc their tumorigenicity completely when 
producing IL-2 and nearly completely when producing 
IFN-y. Therefore. the secretion of cyjtokines can abolish 
tumorigeni~ity of the M3 cells. 
(f) Moderate levels of IFN-y afford no systemic 
protection, high levels of IL-2 afford complete systemic 
protection against a challenge with tumorigeni~ M3 cells 
In another set of experiments mice were immunized 
with high-IL-2-expressing M3 cells (3 x 10J units/lOh cells 
per 24 h); another group was immunized with cells pro- 
ducing IFN-1, at moderate levels. Ad5dllOl4 was used as 
endosomolytic agent in these experiments. Injection of 
the immunizing dose (IO’ cytokine-producing irradiated 
M3 cells) was into the left flank on day 0 and day 7 
foliowed by a challenge with 10’ live tumorigeni~ M3 
cells injected into the right flank on day 14. As can be 
seen from Table V. non-immunized mice developed 
tumors very quickly. They were killed after week 7. The 
IL-2 producers were fully protected. Although moderate 
IFN-y producers nearly completely abolished tumorige- 
nicity of (non-irradiated) M3 cells (see Table IV), no sys- 
temic protection against the challenge with live M3 cells 
was obtained as the values did not differ from those ob- 
tained with non-transferrinfected irradiated M3 cells (un- 
published results). This contrasts with the findings of 
Watanabe et al. (1989) and Gansbacher et al. (1990a,b) 
who used neuroblastomas and fibrosarcomas and found 
a systemic protection in both of these tumor types after 
application of IFN-y-producing ceils. 
(g) Only M3 cells expressing high levels of IL-2 establish 
complete systemic protection against challenges with 
tumorigenic M3 cells 
A striking feature of the data in Table II is that gen- 
erally low levels of cytokine secretion are obtained. A 
notable exception to this is the recent work of Dranoff 
et al. (1993) in which generation of novel rctroviruses 
allows high expression levels of all cytokines tested. The 
claim of these authors that in most previous studies vacci- 
nation with irradiated tumor cells alone would have gen- 
erated systemic antitumor immunity at levels comparable 
to those induced by live transduced cells has serious 
implications. 
High levels of IL-2 secretion of between 2 x 10” and 
10” units/lo” cells per 24 h can be obtained in vitro by 
transferrinfection of murine M3 melanoma cells. The de- 
sired levels of IL-2 production can be adjusted simply by 
mixing the IL-2 expression vector with plasmid devoid 
of the It-2 cDNA. 
That the high level of IL-2 secretion is an important 
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TABLE V 
Protection of immunized DBA/2 mice from M3 melanoma development” 
Immunizations (2 x) Appearance of tumors 
(1 x lo5 cells, irradiated) [weeks (w) after tumor cell] 
IW 2w 3w 4w 5w 6W IW SW Yw 
No immunization 616 616 616 616 616 616 616 
IL-2 100% (dl1014) O/6 O/6 O/6 O/6 O/6 O/6 O/6 016 O/6 
IFN-y 10% (dI1014) 416 516 516 516 516 516 516 516 516 
“Transfer complexes were generated as shown in Table IV for IL-2 100% and IFN-T 10%. IFN-y plasmids were diluted out with parental plasmid 
pSP in a ratio of 10: 90. IL expression was: IL-2 100% = 3 x lo4 u/lo6 cells per 24 h; IFN-y 10% =800 ng/106 cells per 24 h. 
feature for eliciting systemic protection can be seen from 
Table VI. M3 melanoma cells were transferrinfected with 
the IL-2 gene to reach secretion levels of 3 x lo4 units/lo6 
cells per 24 h in vitro. In order to reduce the level of IL-2 
production, the IL-2 plasmid was mixed with the parental 
plasmid pSP which did not contain the CMV IL-2 gene 
construct (in a ratio of 4 : 96). The secretion rate obtained 
was 400 units IL-2 per 106/24 h. For vaccination, groups 
of mice, usually six, were injected with irradiated (2000 
rad) IL-2-producing M3 cells at the two different levels 
indicated above. Injection was into the left flank on day 
0 and day 7, as above, followed by a challenge with lo’, 
3 x lo5 and lo6 live tumorigenic M3 cells injected into 
the right flank on day 14. As shown in Table VI, all non- 
immunized mice developed tumors within 3 weeks. Three 
out of six mice vaccinated with irradiated cells which had 
been transfected with the parental plasmid devoid of the 
IL-2 gene developed tumors, suggesting that transfected 
and irradiated M3 tumor cells were partially immuno- 
genic. Mice vaccinated with irradiated high-level IL-2 
producers afforded complete and lasting protection even 
TABLE VI 
Protection of immunized DBA/2 mice from M3 melanoma development 
after increasing challenge with tumorigenic cells” 
Challenge with 105 3 x lo5 lo6 
cells 
No immunization 616 _ 
PSP 316 
IL-2 (3 x lo4 u) O/6 016 l/4 
IL-2 (4 x 10’ u) O/5 315 415 
Challenge with 10’ KLN205 cells 
IL-2 (3 x lo4 u) 616 _ 
“The transfer complexes were generated as shown in Table IV except 
that Ad5d11014, 8-methoxypsoralen (8-MOP)/UV-irradiated, was used. 
For high-producer M3 cells 6 ug IL-2 plasmid DNA was used. For the 
low IL-2 producers the 6 ug DNA consisted of IL-2 plasmid diluted 
out with the parental plasmid without insert (pSP) in a ratio of 4:Y6. 
Tumor load was scored 3 weeks after tumor challenge. 
with challenges as high as 3 x lo5 cells, but at lo6 cells 
l/4 mice developed a small tumor. By contrast, low 
IL-2-producing cells did not withstand a challenge with 
3 x lo5 cells, 3/5 mice developing tumors. The high IL-2 
producers did not protect against a challenge with a low 
dose of KLN205 cells showing that the protection in the 
above experiments was tumor-specific. 
(h) Conclusions 
The examples given in Tables IV-VI clearly demon- 
strate that transferrinfected M3 cells express cytokines at 
high levels and over a period long enough to suppress 
tumorigenicity of their cells and in the case of high IL-2 
secretors impart systemic and lasting protection against 
a challenge of highly tumorigenic cells. Our results rein- 
force the concerns of Dranoff et al. (1993) and suggest 
that high levels of cytokine production may be necessary 
for high efficacy of ‘tumor vaccines’. 
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